Tags

Type your tag names separated by a space and hit enter

[The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers].
Zhonghua Nei Ke Za Zhi. 2005 Oct; 44(10):741-4.ZN

Abstract

OBJECTIVE

To evaluate the diagnostic value of serum carcinoma markers CA19-9, CA242, CA50 and carcinoembryonic antigens (CEA), fecal K-ras and p53 gene mutation in pancreatic cancer.

METHODS

We collected 136 new cases of pancreatic cancer and 240 patients with benign digestive diseases including 49 patients with benign pancreatic diseases diagnosed in Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Tumor Hospital and Shenyang PLA General Hospital from February 2002 to March 2004. Blood samples were collected and serum carcinoma markers CA19-9, CA242, CA50 and CEA were measured. Fecal K-ras and p53 gene mutation were also measured. We decided the optimal cut-off points with receiver operating characteristic curves and calculated the areas under the curve (AUC).

RESULTS

The AUC of serum CA19-9 and CA242 were 0.855 +/- 0.031 (95% CI 0.794 - 0.916) and 0.859 +/- 0.031 (95% CI 0.799 - 0.920) respectively. The optimal cut-off point for serum CA19-9 was 68 U/ml, with the sensitivity of 84.4% (98/116) and the specificity of 84.3% (145/172) for the diagnosis of pancreatic cancer. The optimal cut-off point for serum CA242 was 25 U/ml, with the sensitivity of 88.4% (84/95) and the specificity of 79.1% (144/182). The sensitivity of fecal K-ras mutation was 77.8%, and the specificity was 82.2%. The sensitivity and specificity of fecal p53 gene mutation were 27.8% and 95.2% respectively. The diagnostic scale of pancreatic cancer was calculated by four variables: serum CA19-9, CA242, fecal K-ras and p53, of which each variable deserved one point if measured positive. The optimal cut-off point for the scale was 2, and the AUC of the diagnostic scale was 0.946 +/- 0.017 (95% CI 0.912 - 0.980).

CONCLUSIONS

Serum CA19-9 and CA242 are valuable diagnostic tools for pancreatic cancer. The diagnostic value will be further improved when they are combined with the measurement of fecal K-ras and p53 gene mutation.

Authors+Show Affiliations

Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't

Language

chi

PubMed ID

16255879

Citation

Wu, Xi, et al. "[The Diagnostic Value of Serum Carcinoma Markers, Fecal K-ras and P53 Gene Mutation in Pancreatic Cancers]." Zhonghua Nei Ke Za Zhi, vol. 44, no. 10, 2005, pp. 741-4.
Wu X, Lu XH, Xu T, et al. [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers]. Zhonghua Nei Ke Za Zhi. 2005;44(10):741-4.
Wu, X., Lu, X. H., Xu, T., Qian, J. M., Zhao, P., Guo, X. Z., Yang, X. O., & Jiang, W. J. (2005). [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers]. Zhonghua Nei Ke Za Zhi, 44(10), 741-4.
Wu X, et al. [The Diagnostic Value of Serum Carcinoma Markers, Fecal K-ras and P53 Gene Mutation in Pancreatic Cancers]. Zhonghua Nei Ke Za Zhi. 2005;44(10):741-4. PubMed PMID: 16255879.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers]. AU - Wu,Xi, AU - Lu,Xing-hua, AU - Xu,Tong, AU - Qian,Jia-ming, AU - Zhao,Ping, AU - Guo,Xiao-zhong, AU - Yang,Xiao-ou, AU - Jiang,Wei-jun, PY - 2005/11/1/pubmed PY - 2006/7/22/medline PY - 2005/11/1/entrez SP - 741 EP - 4 JF - Zhonghua nei ke za zhi JO - Zhonghua Nei Ke Za Zhi VL - 44 IS - 10 N2 - OBJECTIVE: To evaluate the diagnostic value of serum carcinoma markers CA19-9, CA242, CA50 and carcinoembryonic antigens (CEA), fecal K-ras and p53 gene mutation in pancreatic cancer. METHODS: We collected 136 new cases of pancreatic cancer and 240 patients with benign digestive diseases including 49 patients with benign pancreatic diseases diagnosed in Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Tumor Hospital and Shenyang PLA General Hospital from February 2002 to March 2004. Blood samples were collected and serum carcinoma markers CA19-9, CA242, CA50 and CEA were measured. Fecal K-ras and p53 gene mutation were also measured. We decided the optimal cut-off points with receiver operating characteristic curves and calculated the areas under the curve (AUC). RESULTS: The AUC of serum CA19-9 and CA242 were 0.855 +/- 0.031 (95% CI 0.794 - 0.916) and 0.859 +/- 0.031 (95% CI 0.799 - 0.920) respectively. The optimal cut-off point for serum CA19-9 was 68 U/ml, with the sensitivity of 84.4% (98/116) and the specificity of 84.3% (145/172) for the diagnosis of pancreatic cancer. The optimal cut-off point for serum CA242 was 25 U/ml, with the sensitivity of 88.4% (84/95) and the specificity of 79.1% (144/182). The sensitivity of fecal K-ras mutation was 77.8%, and the specificity was 82.2%. The sensitivity and specificity of fecal p53 gene mutation were 27.8% and 95.2% respectively. The diagnostic scale of pancreatic cancer was calculated by four variables: serum CA19-9, CA242, fecal K-ras and p53, of which each variable deserved one point if measured positive. The optimal cut-off point for the scale was 2, and the AUC of the diagnostic scale was 0.946 +/- 0.017 (95% CI 0.912 - 0.980). CONCLUSIONS: Serum CA19-9 and CA242 are valuable diagnostic tools for pancreatic cancer. The diagnostic value will be further improved when they are combined with the measurement of fecal K-ras and p53 gene mutation. SN - 0578-1426 UR - https://www.unboundmedicine.com/medline/citation/16255879/[The_diagnostic_value_of_serum_carcinoma_markers_fecal_K_ras_and_p53_gene_mutation_in_pancreatic_cancers]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&issn=0578-1426&year=2005&vol=44&issue=10&fpage=741 DB - PRIME DP - Unbound Medicine ER -